Hope for hepatitis c relapsers: new Triple-Drug combo shows promise
NCT ID NCT01466192
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new drug called MP-424 (telaprevir) added to standard therapy (peginterferon and ribavirin) for people with genotype 2 hepatitis C whose infection came back after previous treatment. The goal was to see if the combination could clear the virus for good. The trial enrolled 108 adults and measured whether the virus stayed undetectable 24 weeks after treatment ended.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Telaprevir (MP-424) combined with peginterferon alfa-2b and ribavirin
What this could lead to
If successful, this combination could offer a more effective retreatment option for people with genotype 2 hepatitis C who relapsed after previous therapy, potentially leading to higher cure rates.
What could go wrong
This is a completed Phase 3 trial with 108 participants, so results are available but may not apply to all patients. Side effects from the drug combination (e.g., anemia, rash) are possible, and the regimen is intensive with multiple drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Toranomon Hospital
Minato-ku, Tokyo, Japan